Pancreas Club, Inc. “How I Do It” Session: Imaging of Benign and Malignant Pancreatic Disease: The Year 2001 MODERATOR: Charles J. Yeo, M.D., Professor of Surgery and Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland PARTICIPANTS: Karen M. Horton, M.D., Johns Hopkins Medical Institutions, Baltimore, Maryland; Maurits J. Wiersema, M.D., Mayo Clinic, Rochester, Minnesota; Caroline Reinhold, M.D., M.Sc., McGill University Health Centre, McGill University, Montreal, Quebec, Canada; and Naomi Alazraki, M.D., Atlanta Veterans Affairs Medical Center/ Emory University, Atlanta, Georgia
INTRODUCTION This year’s “How I Do It” session of the Pancreas Club dealt with the topic of imaging of benign and malignant pancreatic diseases, updating the field to the year 2001. It was thought that this topic was particularly relevant because of technologic advances in the fields of computed tomography (CT), endoscopic ultrasonography EUS), magnetic resonance imaging (MRI), and positron emission tomography (PET). The session featured four speakers: (1) Karen M. Horton, M.D., from The Johns Hopkins Medical Institutions, discussed the current state of CT imaging, focusing on multidetector CT and three-dimen-
sional imaging of the pancreas; (2) Maurits J. Wiersema, M.D., from The Mayo Clinic in Rochester, Minnesota, discussed the use of EUS, focusing on chronic pancreatitis, cystic pancreatic neoplasms, and pancreatic adenocarcinoma; (3) Caroline Reinhold, M.D., M.Sc., from the McGill University Health Center in Montreal, discussed MRI, focusing on anatomic variants, chronic pancreatitis, and pancreatic neoplasia; and (4) Naomi Alazraki, M.D., from the Atlanta VA Medical Center and Emory University, discussed imaging of pancreatic cancer with the use of fluorine-18 fluorodeoxyglucose PET. Brief synopses of these four presentations follow.
Presented at the Annual Meeting of the Pancreas Club, Inc., Atlanta, Georgia, May 20, 2001. © 2002 The Society for Surgery of the Alimentary Tract, Inc. Published by Elsevier Science Inc.
1091-255X/02/$—see front matter PII: S 1 0 9 1 - 2 5 5 X ( 0 1 ) 0 0 0 3 9 - 7
125